ALZN Alzamend Neuro: Net earnings per share for the last 12 months

Alzamend Neuro, Inc. (ALZN) seeks to solidify its status as an innovator in the fight against dementia by establishing scientific authority through comprehensive therapy methods. A key development vector is the expansion of the AL001 lithium drug portfolio to capture the neuropharmaceutical sector. The rolling year net income per share trend confirms these ambitions, where the value 73.70 serves as the baseline indicator. Currently, demand is limited to research due to an acute shortage of effective medications.
Financial and market metric breakdowns for Alzamend Neuro (ALZN)

This indicator measures the annual dynamics of net profit per share, determining the rate of change in return on equity. By analyzing the 12-month EPS YoY history, an investor assesses the sustainability of financial results. The metric is calculated as the percentage deviation of the current TTM value from the same period last year. For Alzamend Neuro, Inc. (ALZN), this reflects the efficiency of capitalizing patents in the field of neurodegenerative disease therapy. Growth in this indicator confirms the successful monetization of the company's intellectual property.